Monocytopenia As an Adverse Prognosticator in Vexas Syndrome
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Matthew J. Koster(Mayo Clinic in Arizona), Horatiu Olteanu(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Allison M. Bock(Mayo Clinic), Jenna A. Fernandez(Mayo Clinic in Florida), Kenneth J. Warrington(Mayo Clinic), Jennifer L. Herrick(Mayo Clinic in Arizona), Christy M. Finke(Mayo Clinic), Terra L. Lasho(Mayo Clinic), Kaaren K. Reichard(Mayo Clinic), Kebede Begna(Mayo Clinic)
Cited by 5
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447